

Stiripentol (Diacomit)

Coverage Criteria:

1. Prescribed by or in consultation with a neurologist; and,
2. Patient is diagnosed Dravet syndrome; and,
3. Patient is not adequately controlled on clobazam and there is documentation the patient has been adherent to prescribed clobazam regimen; and,
4. Clobazam will be prescribed in combination with Diacomit; and,
5. Documentation that baseline neutrophil and platelet counts are within normal limits; and,
6. Prescribed within the FDA approved dosing regimen.

Coverage Duration:

Initial authorizations will be provided for 6 months

Reauthorizations will be provided for 12 months

Renewal Criteria:

1. Patient has been seen by their prescriber in the past 12 months; and,
2. Patient continues concomitant use of clobazam; and,
3. Documentation neutrophil and platelet counts have been assessed in the past 6 months and are within normal limits; and,
4. Prescribed within the FDA approved dosing regimen.